PE20091317A1 - Antagonista del receptor opioide selectivo kappa - Google Patents

Antagonista del receptor opioide selectivo kappa

Info

Publication number
PE20091317A1
PE20091317A1 PE2009000036A PE2009000036A PE20091317A1 PE 20091317 A1 PE20091317 A1 PE 20091317A1 PE 2009000036 A PE2009000036 A PE 2009000036A PE 2009000036 A PE2009000036 A PE 2009000036A PE 20091317 A1 PE20091317 A1 PE 20091317A1
Authority
PE
Peru
Prior art keywords
opioid receptor
selective opioid
receptor antagonist
compound
kappa
Prior art date
Application number
PE2009000036A
Other languages
English (en)
Inventor
Buezo Nuria Diaz
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20091317A1 publication Critical patent/PE20091317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

REFERIDA AL COMPUESTO (S)-3-FLUORO-4-[4-[2-(3,5-DIMETILFENIL)PIRROLIDIN-1-IL-METIL]FENOXI]BENZAMIDA Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS UN INHIBIDRO DE LA REABSORCION DE NOREPINEFRINA TRICICLICA DE AMINA TERCIARIA SELECCIONADA DE AMITRIPTILINA, CLOMIPRAMINA, DOXEPINA, IMIPRAMINA Y (+)-TRIMIPRAMINA. DICHO COMPUESTO ES ANTAGONISTA DEL RECEPTOR OPIOIDE SELECTIVO KAPPA UTIL EN EL TRATAMIENTO DE CIRROSIS HAPATICA, CANCER DE HIGADO, ENFERMEDAD CARDIACA CORONARIA, SINDROMA DE ALCOHOL FETAL, ENTRE OTROS
PE2009000036A 2008-01-22 2009-01-13 Antagonista del receptor opioide selectivo kappa PE20091317A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
PE20091317A1 true PE20091317A1 (es) 2009-09-03

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000036A PE20091317A1 (es) 2008-01-22 2009-01-13 Antagonista del receptor opioide selectivo kappa

Country Status (33)

Country Link
US (2) US7709522B2 (es)
EP (1) EP2252581B1 (es)
JP (1) JP5345637B2 (es)
KR (1) KR101172170B1 (es)
CN (1) CN101925576B (es)
AR (1) AR070158A1 (es)
AU (1) AU2009206653B2 (es)
BR (1) BRPI0907382B8 (es)
CA (1) CA2713025C (es)
CO (1) CO6290644A2 (es)
CY (1) CY1113071T1 (es)
DK (1) DK2252581T3 (es)
DO (1) DOP2010000222A (es)
EA (1) EA017484B1 (es)
EC (1) ECSP10010365A (es)
ES (1) ES2388708T3 (es)
HK (1) HK1146822A1 (es)
HR (1) HRP20120558T1 (es)
IL (1) IL206038A (es)
JO (1) JO2797B1 (es)
MA (1) MA32751B1 (es)
MX (1) MX2010007849A (es)
MY (1) MY163014A (es)
NZ (1) NZ586225A (es)
PE (1) PE20091317A1 (es)
PL (1) PL2252581T3 (es)
PT (1) PT2252581E (es)
SI (1) SI2252581T1 (es)
TN (1) TN2010000306A1 (es)
TW (1) TWI422369B (es)
UA (1) UA100715C2 (es)
WO (1) WO2009094260A1 (es)
ZA (1) ZA201003908B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2252581T3 (da) * 2008-01-22 2012-07-16 Lilly Co Eli Kappa-selektiv opioidreceptorantagonist
AU2009206936A1 (en) * 2008-01-22 2009-07-30 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
WO2013040321A1 (en) * 2011-09-15 2013-03-21 University Of Kansas Kappa opioid receptor effectors and uses thereof
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US9512105B2 (en) 2011-12-09 2016-12-06 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
AU2014268361B2 (en) * 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
KR102656163B1 (ko) 2017-03-17 2024-04-08 더 스크립스 리서치 인스티튜트 카파 오피오이드 수용체 길항제 및 그와 관련된 제품 및 방법
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
KR20240004857A (ko) 2021-05-04 2024-01-11 얀센 파마슈티칼즈, 인코포레이티드 우울증 치료를 위한 조성물 및 방법
WO2023131921A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023131920A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
TW202400135A (zh) * 2022-03-07 2024-01-01 美商健生醫藥公司 包含阿替卡普蘭之組成物
US20230348377A1 (en) * 2022-03-07 2023-11-02 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) * 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
WO2002029418A1 (en) * 2000-10-05 2002-04-11 Hanns Mohler Selective anxiolytic therapeutic agents
US6528518B2 (en) 2000-12-21 2003-03-04 The Mclean Hospital Corporation Treatment of depression with kappa receptor antagonists
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
KR100865410B1 (ko) * 2002-03-28 2008-10-24 위시스 테크놀로지 파운데이션, 인크. 진정 및 운동실조 효과가 감소된 항불안제
CA2499690C (en) * 2002-09-19 2011-05-24 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
BRPI0407616A (pt) 2003-03-07 2006-02-14 Lilly Co Eli composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"
JP2006519855A (ja) 2003-03-07 2006-08-31 イーライ リリー アンド カンパニー オピオイド受容体アンタゴニスト
EP1697307B1 (en) 2003-12-12 2014-03-12 Eli Lilly & Company Opioid receptor antagonists
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1730140B1 (en) 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
EP1729759A4 (en) 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORIN DERIVATIVES AND USES THEREOF
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
WO2007115975A2 (de) 2006-04-04 2007-10-18 Holger Lars Hermann Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
CN103980151A (zh) 2006-08-09 2014-08-13 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
DK2252581T3 (da) * 2008-01-22 2012-07-16 Lilly Co Eli Kappa-selektiv opioidreceptorantagonist

Also Published As

Publication number Publication date
JO2797B1 (en) 2014-03-15
ES2388708T3 (es) 2012-10-17
UA100715C2 (ru) 2013-01-25
BRPI0907382B8 (pt) 2021-05-25
TW200936129A (en) 2009-09-01
CN101925576B (zh) 2013-02-06
IL206038A (en) 2013-11-28
AR070158A1 (es) 2010-03-17
EP2252581A1 (en) 2010-11-24
TN2010000306A1 (en) 2011-11-11
AU2009206653B2 (en) 2013-07-18
CA2713025A1 (en) 2009-07-30
DK2252581T3 (da) 2012-07-16
PT2252581E (pt) 2012-08-31
PL2252581T3 (pl) 2012-10-31
JP5345637B2 (ja) 2013-11-20
US20090186873A1 (en) 2009-07-23
MY163014A (en) 2017-07-31
BRPI0907382A2 (pt) 2015-07-21
US7709522B2 (en) 2010-05-04
HK1146822A1 (en) 2011-07-15
NZ586225A (en) 2012-05-25
EA201070877A1 (ru) 2010-12-30
EA017484B1 (ru) 2012-12-28
MA32751B1 (fr) 2011-11-01
HRP20120558T1 (hr) 2012-10-31
ZA201003908B (en) 2011-11-30
CA2713025C (en) 2012-12-04
ECSP10010365A (es) 2010-08-31
US8173695B2 (en) 2012-05-08
CO6290644A2 (es) 2011-06-20
CY1113071T1 (el) 2016-04-13
KR20100095639A (ko) 2010-08-31
AU2009206653A1 (en) 2009-07-30
CN101925576A (zh) 2010-12-22
IL206038A0 (en) 2010-11-30
KR101172170B1 (ko) 2012-08-07
SI2252581T1 (sl) 2012-09-28
JP2011524850A (ja) 2011-09-08
WO2009094260A1 (en) 2009-07-30
TWI422369B (zh) 2014-01-11
EP2252581B1 (en) 2012-06-20
BRPI0907382B1 (pt) 2020-03-10
US20100197669A1 (en) 2010-08-05
DOP2010000222A (es) 2015-11-15
MX2010007849A (es) 2010-08-09

Similar Documents

Publication Publication Date Title
PE20091317A1 (es) Antagonista del receptor opioide selectivo kappa
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
PE20120812A1 (es) Compuestos vinil indazolilo
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
HRP20120129T8 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
GT200400174A (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4
PE20050761A1 (es) Polimorfo cristalino de una sal de bisulfato como antagonista del receptor de trombina
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
ES2570374T3 (es) Antagonistas del receptor opioide periférico y usos de los mismos
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
MA37886B1 (fr) Nouvelles pyridinones bicycliques
AR069554A1 (es) Compuesto triciclico de amino benzoimidazol
CL2010000059A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer.
SV2011003916A (es) Nuevas lactamas como inhibidores de beta secretasa
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
CL2009001414A1 (es) Procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-ona sin aislacion de compuestos intermediarios; util para la sintesis de ivabradina.
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
SE0401655D0 (sv) New compounds
BR0309668A (pt) Imidazolinilmetil aralquilsulfonamidas

Legal Events

Date Code Title Description
FG Grant, registration